Clozapine monitoring requirements: is it time for an update?

Emilio Fernandez-Egea,Robert A. McCutcheon
DOI: https://doi.org/10.1192/bjp.2024.150
2024-10-04
The British Journal of Psychiatry
Abstract:Oloyede and colleagues advocate for updating haematological monitoring requirements for clozapine, arguing that current protocols overestimate the risk of clozapine-induced agranulocytosis. Their research suggests that stringent monitoring may unnecessarily limit access to clozapine, a crucial treatment for resistant schizophrenia. The editorial supports calls for international consensus to carefully weigh the pros and cons of relaxing monitoring guidelines while ensuring comprehensive care for patients.
psychiatry
What problem does this paper attempt to address?